Who Qualifies for GLP-1 Weight Loss Treatment? (2026 Eligibility Guide)
FDA-approved GLP-1 medications for chronic weight management have specific eligibility criteria. Here's the full picture — BMI thresholds, qualifying conditions, absolute contraindications, and how the consultation actually works.
The two-tier eligibility framework
FDA labeling for semaglutide (Wegovy) and tirzepatide (Zepbound) for chronic weight management uses a two-tier eligibility model:
- Tier 1 — BMI ≥ 30 (obesity). Adults with BMI of 30 or higher qualify on BMI alone, with no comorbidity required.
- Tier 2 — BMI 27–29.9 (overweight) + comorbidity. Adults with BMI between 27 and 29.9 qualify if they also have at least one weight-related comorbid condition.
The qualifying comorbidities most commonly accepted:
- Type 2 diabetes (T2D)
- Hypertension (high blood pressure)
- Dyslipidemia (high cholesterol or triglycerides)
- Cardiovascular disease (heart disease, prior heart attack or stroke)
- Obstructive sleep apnea (OSA)
- Polycystic ovary syndrome (PCOS) with insulin resistance
- Non-alcoholic fatty liver disease (NAFLD/MASLD)
Compounded GLP-1 prescribing in our clinic follows the same medical eligibility framework. We don't loosen the criteria for compounded therapy — the BMI and comorbidity thresholds matter regardless of regulatory pathway.
Absolute contraindications — when GLP-1 is not safe
These are conditions that rule out GLP-1 therapy regardless of BMI or comorbidities. The boxed warning on FDA labels exists because of these:
- Personal or family history of medullary thyroid carcinoma (MTC). GLP-1 medications carry a class boxed warning for thyroid C-cell tumors based on rodent studies.
- Multiple endocrine neoplasia syndrome type 2 (MEN-2). Same boxed warning rationale.
- Known hypersensitivity to semaglutide, tirzepatide, or any formulation excipient.
- Current pregnancy or breastfeeding. GLP-1 medications are not recommended during pregnancy or lactation; safety data are insufficient.
- Active pancreatitis or history of severe pancreatitis.
Relative contraindications — case-by-case evaluation
These conditions don't automatically rule out treatment but require careful evaluation and may modify the protocol:
- Severe gastroparesis or other significant GI motility disorders. GLP-1 slows gastric emptying, which can worsen these conditions.
- Active suicidal ideation or recent significant psychiatric instability. Some patients on GLP-1 have reported mood changes; the FDA continues to monitor.
- End-stage kidney disease. Dose adjustments and additional monitoring may be required.
- End-stage liver disease. Same.
- Type 1 diabetes. GLP-1 isn't FDA-approved for T1D, though some endocrinologists use it off-label as an adjunct.
- Active gallbladder disease. GLP-1 may increase gallstone risk; monitoring is appropriate.
- Recent bariatric surgery. Coordinated care with the bariatric surgeon is required.
- Eating disorders. History of binge eating disorder, anorexia, or bulimia warrants screening before initiating treatment.
- Diabetic retinopathy. Rapid weight loss can transiently worsen retinopathy; ophthalmology coordination matters.
How the eligibility check actually works at NHWL
- The 2-minute qualifying quiz. Online, no commitment. Captures BMI, primary goal, and a few screening questions.
- The medical intake form. Detailed medical history including current medications, prior surgeries, family history, allergies, and a screening checklist for absolute and relative contraindications.
- Dr. Sharma's review. The physician reviews intake before the visit. If you're clearly not a candidate (an absolute contraindication marked), we tell you before the visit and refund the medication portion of any prepaid trial.
- The initial consultation. 20–30 minute visit (in-person or video) to discuss eligibility, alternatives, and goals.
- The decision. Eligible: prescription is written. Not eligible for GLP-1: we discuss alternatives and may refer you elsewhere.
What if you're not eligible — what then?
If GLP-1 isn't right for you, that doesn't mean we can't help. Some alternatives we discuss:
- Nutrition counseling and structured weight management programs — particularly for patients below BMI 27.
- B12 / lipotropic injection support — energy and metabolic support without GLP-1.
- Referral to bariatric surgery evaluation — for patients with BMI ≥ 40, or BMI ≥ 35 with severe comorbidities.
- Referral to endocrinology or specialty care — for patients whose primary issue is poorly controlled diabetes, hormone imbalance, or another condition that needs different management first.
- Re-evaluation at a future date — if circumstances change (weight gain that brings BMI to threshold, development of a qualifying comorbidity, etc.), we re-evaluate.
Frequently asked questions
What BMI do I need to qualify?
BMI ≥ 30 qualifies on its own. BMI 27–29.9 qualifies if you also have a weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease, PCOS with insulin resistance, NAFLD).
What are the absolute contraindications?
Personal or family history of medullary thyroid carcinoma (MTC), MEN-2 syndrome, hypersensitivity to the active ingredient, current pregnancy or breastfeeding, and active pancreatitis. Severe gastroparesis and other conditions are case-by-case.
Does type 2 diabetes qualify me?
Yes. T2D is one of the qualifying comorbidities. If your endocrinologist already manages your diabetes with brand-name GLP-1, continuing that path is usually preferable.
Does PCOS qualify me?
PCOS itself isn't an FDA indication, but PCOS often presents with insulin resistance and overweight/obesity that meet eligibility under the BMI 27+ comorbidity pathway.
What if my BMI is below 27?
GLP-1 weight loss therapy is not standard practice below BMI 27. We won't prescribe in that range. We may suggest nutrition support and re-evaluate if circumstances change.
How does the eligibility check work?
2-minute quiz → medical intake form → Dr. Sharma's review → initial consultation → decision. The intake screens for contraindications before the visit so we don't waste your time.
Will I be denied for a complicated history?
Not automatically. Many conditions are manageable with protocol adjustments. We deny only when there's an absolute contraindication or the risk-benefit doesn't favor proceeding.
This article is informational only and not medical advice. Eligibility for GLP-1 therapy is determined during the medical consultation by Dr. Anjmun Sharma. Individual results vary. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company.